Gyalatx
Barcelona, ES · Founded 2020 · 8 employees on LinkedIn · 1 known investors
Gyala Therapeutics is a biotech company developing GYA01, an investigational CAR-T cell therapy for hematologic cancers including acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). Founded in 2020 as a spin-off of Hospital Clínic Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), it builds on these institutions' experience in CAR-T therapies.
Investors · 1
Frequently asked questions
- What does Gyalatx do?
- Gyala Therapeutics is a biotech company developing GYA01, an investigational CAR-T cell therapy for hematologic cancers including acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). Founded in 2020 as a spin-off of Hospital Clínic Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), it builds on these institutions' experience in CAR-T therapies.
- Who are Gyalatx's investors?
- Gyalatx's investors include Invivo Capital Partners.
- Where is Gyalatx headquartered?
- Gyalatx is headquartered in Barcelona, ES.